Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent.
## Primary Indications
* Symptomatic relief of abdominal pain and cramps associated with spasms of the gastrointestinal tract, particularly in conditions like irritable bowel syndrome.
* Management of dysmenorrhea (menstrual cramps).
## Adult Dosing
* **Mefenamic Acid:** Typically 250 mg to 500 mg orally every 6 to 8 hours as needed. Do not exceed 1500 mg per day for short-term use.
* **Hyoscine Butylbromide:** Typically 10 mg to 20 mg orally up to 4 times daily.
* The specific dosing of the combination product will depend on the available strengths and the prescriber's judgment, guided by local protocols.
## Pediatric Dosing
There is **limited established pediatric dosing** for this combination product. Mefenamic acid dosing in children is typically based on weight, but hyoscine butylbromide dosing is less well-defined in younger populations. Use in children should be at the discretion of a pediatrician and based on careful risk-benefit assessment.
## Dose Adjustments
* **Renal Impairment:** Mefenamic acid should be used with caution and potentially at reduced doses in patients with moderate to severe renal impairment.
* **Hepatic Impairment:** Mefenamic acid should be used with caution in patients with hepatic impairment.
* **Elderly:** Elderly patients may be more susceptible to the adverse effects of NSAIDs, including gastrointestinal bleeding and renal toxicity. Use with caution and consider lower doses.
## Contraindications
* Hypersensitivity to mefenamic acid, hyoscine butylbromide, or any component of the formulation.
* Active gastrointestinal ulceration or inflammation.
* History of NSAID-induced bronchospasm, urticaria, or allergic rhinitis.
* Severe renal or hepatic impairment.
* Myasthenia gravis.
* Tachycardia, glaucoma, prostatic hypertrophy (relative contraindications for hyoscine butylbromide).
* Intestinal obstruction or paralytic ileus.
## Adverse Effects
* **Mefenamic Acid:** Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain, dyspepsia), dyspepsia, headache, dizziness, rash, renal impairment, elevated liver enzymes, increased risk of cardiovascular thrombotic events, gastrointestinal bleeding.
* **Hyoscine Butylbromide:** Dry mouth, blurred vision, constipation, urinary retention, tachycardia, drowsiness, dizziness.
## Key Drug Interactions
* **Mefenamic Acid:**
* Anticoagulants (e.g., warfarin): Increased risk of bleeding.
* Corticosteroids: Increased risk of gastrointestinal ulceration and bleeding.
* SSRIs: Increased risk of gastrointestinal bleeding.
* ACE inhibitors, ARBs, diuretics: Reduced antihypertensive effect and increased risk of renal impairment.
* Lithium: Increased lithium levels.
* Methotrexate: Increased methotrexate toxicity.
* **Hyoscine Butylbromide:** Additive anticholinergic effects with other drugs possessing anticholinergic properties (e.g., tricyclic antidepressants, antihistamines, antipsychotics).
## Monitoring
* **Gastrointestinal:** Monitor for signs and symptoms of bleeding or ulceration.
* **Renal:** Monitor renal function, especially in patients with pre-existing renal disease or those on concomitant nephrotoxic agents.
* **Hepatic:** Monitor liver function tests periodically.
* **Cardiovascular:** Be aware of the increased risk of cardiovascular events with NSAID use.
* **Hydration and Electrolytes:** Especially important if diarrhea is present.
## Clinical Pearls
* Meftal spas should be used for the shortest duration necessary to control symptoms.
* Lowest effective dose should be used.
* Consider gastroprotection (e.g., PPI) in patients at high risk of GI bleeding.
* Concomitant use with other NSAIDs should be avoided.
* Effectiveness and safety in pediatric populations are not well-established.
**Disclaimer:** This information is intended for clinical pharmacists and should not substitute for complete prescribing information or professional judgment. Always consult the most current product monograph or relevant clinical guidelines for the most up-to-date and comprehensive information before prescribing.
